{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:18:20Z","timestamp":1785766700466,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-022-06717-8","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T13:02:52Z","timestamp":1659790972000},"page":"1731-1737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin"],"prefix":"10.1007","volume":"306","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5283-9292","authenticated-orcid":false,"given":"Ginevra","family":"Mills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-7708","authenticated-orcid":false,"given":"Michael H.","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"6717_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","volume":"44","author":"A Golan","year":"1989","unstructured":"Golan A et al (1989) Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 44:430\u2013440","journal-title":"Obstet Gynecol Surv"},{"key":"6717_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.rbmo.2020.06.004","volume":"41","author":"K Rotshenker-Olshinka","year":"2020","unstructured":"Rotshenker-Olshinka K et al (2020) Trends in ovarian hyperstimulation syndrome hospitalization rates in the USA: an ongoing concern. Reprod Biomed Online 41:357\u2013360","journal-title":"Reprod Biomed Online"},{"key":"6717_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","volume":"85","author":"EG Papanikolaou","year":"2006","unstructured":"Papanikolaou EG et al (2006) Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 85:112\u2013120","journal-title":"Fertil Steril"},{"key":"6717_CR4","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S1701-2163(15)30417-5","volume":"36","author":"S Corbett","year":"2014","unstructured":"Corbett S et al (2014) The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 36:1024\u20131033","journal-title":"J Obstet Gynaecol Can"},{"key":"6717_CR5","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.fertnstert.2014.01.019","volume":"101","author":"HM Fatemi","year":"2014","unstructured":"Fatemi HM et al (2014) Severe Ovarian Hyperstimulation Syndrome after Gonadotropin-Releasing Hormone (Gnrh) Agonist Trigger And \u201cFreeze-All\u201d Approach in Gnrh Antagonist Protocol. Fertil Steril 101:1008\u20131011","journal-title":"Fertil Steril"},{"key":"6717_CR6","first-page":"CD012103","volume":"1","author":"S Mourad","year":"2017","unstructured":"Mourad S, Brown J, Farquhar C (2017) Interventions for the prevention of Ohss in art cycles: an overview of cochrane reviews. Cochrane Database Syst Rev 1:CD012103","journal-title":"Cochrane Database Syst Rev"},{"key":"6717_CR7","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/humrep\/15.9.1965","volume":"15","author":"J Itskovitz-Eldor","year":"2000","unstructured":"Itskovitz-Eldor J, Kol S, Mannaerts B (2000) Use of a Single Bolus of Gnrh Agonist Triptorelin to Trigger Ovulation after Gnrh Antagonist Ganirelix Treatment in Women Undergoing Ovarian Stimulation for Assisted Reproduction, with Special Reference to the Prevention of Ovarian Hyperstimulation Syndrome: Preliminary Report. Hum Reprod 15:1965\u20131968","journal-title":"Hum Reprod"},{"key":"6717_CR8","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1210\/jc.2007-0409","volume":"92","author":"C Alvarez","year":"2007","unstructured":"Alvarez C et al (2007) Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931\u20132937","journal-title":"J Clin Endocrinol Metab"},{"key":"6717_CR9","first-page":"CD008605","volume":"11","author":"H Tang","year":"2016","unstructured":"Tang H et al (2016) Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 11:CD008605","journal-title":"Cochrane Database Syst Rev"},{"key":"6717_CR10","first-page":"281","volume":"17","author":"T Tsunoda","year":"2003","unstructured":"Tsunoda T et al (2003) Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, Docarpamine. Gynecol Endocrinol 17:281\u2013286","journal-title":"Gynecol Endocrinol"},{"key":"6717_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","volume":"17","author":"C Carizza","year":"2008","unstructured":"Carizza C et al (2008) Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17:751\u2013755","journal-title":"Reprod Biomed Online"},{"key":"6717_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejogrb.2005.01.009","volume":"122","author":"M Manno","year":"2005","unstructured":"Manno M et al (2005) Cabergoline: a safe, easy, cheap, and effective drug for prevention\/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Bio 122:127\u2013128","journal-title":"Eur J Obstet Gynecol Reprod Bio"},{"key":"6717_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/09513590.2017.1391206","volume":"34","author":"MH Dahan","year":"2018","unstructured":"Dahan MH, Tannus S, Seyhan A, Tan SL, Ata B (2018) Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation. Gynecol Endocrinol 34:252\u2013255","journal-title":"Gynecol Endocrinol"},{"key":"6717_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.rbmo.2019.04.014","volume":"39","author":"G Shrem","year":"2019","unstructured":"Shrem G et al (2019) Use of cabergoline and post-collection Gnrh antagonist administration for prevention of ovarian hyperstimulation syndrome. Reprod Biomed Online 39:433\u2013438","journal-title":"Reprod Biomed Online"},{"issue":"1169","key":"6717_CR15","first-page":"e15","volume":"92","author":"NL Rollene","year":"2009","unstructured":"Rollene NL et al (2009) Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 92(1169):e15\u2013e17","journal-title":"Fertil Steril"},{"key":"6717_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.rbmo.2009.09.021","volume":"19","author":"TG Lainas","year":"2009","unstructured":"Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E et al (2009) Live births after management of severe Ohss by Gnrh antagonist administration in the luteal phase. Reprod Biomed Online 19:789\u2013795","journal-title":"Reprod Biomed Online"},{"key":"6717_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1472-6483(10)60419-1","volume":"18","author":"TG Lainas","year":"2009","unstructured":"Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Iliadis GS et al (2009) Management of severe Ohss using Gnrh antagonist and blastocyst cryopreservation in Pcos patients treated with long protocol. Reprod Biomed Online 18:15\u201320","journal-title":"Reprod Biomed Online"},{"key":"6717_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00404-019-05163-3","volume":"300","author":"C Zeng","year":"2019","unstructured":"Zeng C et al (2019) The effect of luteal Gnrh antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study. Arch Gynecol Obstet 300:223\u2013233","journal-title":"Arch Gynecol Obstet"},{"key":"6717_CR19","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/humrep\/det114","volume":"28","author":"GT Lainas","year":"2013","unstructured":"Lainas GT et al (2013) Pregnancy and neonatal outcomes following luteal Gnrh antagonist administration in patients with severe early OHSS. Hum Reprod 28:1929\u20131942","journal-title":"Hum Reprod"},{"key":"6717_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejogrb.2013.10.027","volume":"172","author":"MH Dahan","year":"2014","unstructured":"Dahan MH et al (2014) A Comparison of Outcomes from in Vitro Fertilization Cycles Stimulated with Either Recombinant Luteinizing Hormone (Lh) or Human Chorionic Gonadotropin Acting as an Lh Analogue Delivered as Human Menopausal Gonadotropins, in Subjects with Good or Poor Ovarian Reserve: a retrospective analysis. Eur J Obstet Gynecol Reprod Biol 172:70\u201373","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"6717_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s10815-014-0334-9","volume":"31","author":"BI Rose","year":"2014","unstructured":"Rose BI (2014) Approaches to oocyte retrieval for advanced reproductive technology cycles planning to utilize in vitro maturation: a review of the many choices to be made. J Assist Reprod Genet 31:1409\u20131419","journal-title":"J Assist Reprod Genet"},{"key":"6717_CR22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/09513590.2018.1460346","volume":"34","author":"P Drakopoulos","year":"2018","unstructured":"Drakopoulos P et al (2018) Does the type of Gnrh analogue used, affect live birth rates in women with endometriosis undergoing Ivf\/Icsi treatment, according to the rafs stage? Gynecol Endocrinol 34:884\u2013889","journal-title":"Gynecol Endocrinol"},{"key":"6717_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/09513590.2015.1092136","volume":"32","author":"DM Dakhly","year":"2016","unstructured":"Dakhly DM, Bayoumi YA, Allah SHG (2016) Which Is the Best Ivf\/Icsi Protocol to Be Used in Poor Responders Receiving Growth Hormone as an Adjuvant Treatment? A Prospective Randomized Trial. Gynecol Endocrinol 32:116\u2013119","journal-title":"Gynecol Endocrinol"},{"key":"6717_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.fertnstert.2013.09.035","volume":"101","author":"SK Sunkara","year":"2014","unstructured":"Sunkara SK et al (2014) Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Fertil Steril 101:147\u2013153","journal-title":"Fertil Steril"},{"key":"6717_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.fertnstert.2016.05.019","volume":"106","author":"L Londra","year":"2016","unstructured":"Londra L et al (2016) Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization? Fertil Steril 106:666\u2013672","journal-title":"Fertil Steril"},{"key":"6717_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S1472-6483(10)60652-9","volume":"13","author":"G Griesinger","year":"2006","unstructured":"Griesinger G (2006) Gnrh-antagonists in ovarian stimulation for Ivf in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13:628\u2013638","journal-title":"Reprod Biomed Online"},{"key":"6717_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.steroids.2008.01.017","volume":"73","author":"C Stocco","year":"2008","unstructured":"Stocco C (2008) Aromatase expression in the ovary: hormonal and molecular regulation. Steroids 73:473\u2013487","journal-title":"Steroids"},{"key":"6717_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.rbmo.2013.04.014","volume":"27","author":"LJ Ding","year":"2013","unstructured":"Ding LJ et al (2013) Withdrawal of Gnrh agonist decreases oestradiol and VEGF concentrations in high responders. Reprod Biomed Online 27:131\u2013139","journal-title":"Reprod Biomed Online"},{"key":"6717_CR29","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10815-017-1010-7","volume":"34","author":"Y Prapas","year":"2017","unstructured":"Prapas Y et al (2017) Gnrh Antagonist Administered Twice the Day before Hcg Trigger Combined with a Step-Down Protocol May Prevent Ohss in Ivf\/Icsi Antagonist Cycles at Risk for Ohss without Affecting the Reproductive Outcomes: a prospective randomized control trial. J Assist Reprod Genet 34:1537\u20131545","journal-title":"J Assist Reprod Genet"},{"key":"6717_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.fertnstert.2006.01.046","volume":"86","author":"B Asimakopoulos","year":"2006","unstructured":"Asimakopoulos B et al (2006) Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril 86:636\u2013641","journal-title":"Fertil Steril"},{"key":"6717_CR31","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.fertnstert.2009.09.032","volume":"94","author":"N Winkler","year":"2010","unstructured":"Winkler N et al (2010) Gonadotropin releasing hormone antagonists suppress aromatase and anti-m\u00fcllerian hormone expression in human granulosa cells. Fertil Steril 94:1832\u20131839","journal-title":"Fertil Steril"},{"key":"6717_CR32","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1093\/humrep\/12.12.2756","volume":"12","author":"A Lee","year":"1997","unstructured":"Lee A et al (1997) Vascular endothelial growth factor production by human luteinized granulosa cells in vitro. Hum Reprod 12:2756\u20132761","journal-title":"Hum Reprod"},{"key":"6717_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.fertnstert.2010.08.045","volume":"95","author":"B Yu","year":"2011","unstructured":"Yu B, Ruman J, Christman G (2011) The role of peripheral gonadotropin-releasing hormone receptors in female reproduction. Fertil Steril 95:465\u2013473","journal-title":"Fertil Steril"},{"key":"6717_CR34","doi-asserted-by":"publisher","first-page":"90359","DOI":"10.1371\/journal.pone.0090359","volume":"9","author":"J Haas","year":"2014","unstructured":"Haas J et al (2014) Gnrh agonist Vs. Hcg for triggering of ovulation-differential effects on gene expression in human granulosa cells. PLoS ONE 9:90359","journal-title":"PLoS ONE"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06717-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T04:09:06Z","timestamp":1664338146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06717-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["6717"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06717-8","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest related to this article. No funding was available for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of McGill University Health Center # 2019\u20135129<i>.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Being a retrospective study, an informed consent waiver was obtained from the director of professional services of the MUHC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Being a retrospective study, consent to publish was obtained from the director of professional services of the MUHC.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}